Could a biobank unlock secrets of rare kidney stone diseases?
NCT ID NCT02026388
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This study creates a biobank of blood, urine, and tissue samples from people with rare kidney stone diseases—primary hyperoxaluria, cystinuria, APRT deficiency, and Dent disease—and their family members. By storing these samples, researchers hope to enable future studies that could improve diagnosis and treatment. The goal is to build a resource that helps scientists better understand these rare conditions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this biobank could provide a valuable resource for researchers studying rare kidney stone diseases, potentially leading to better understanding and new treatments.
- What could go wrong
- This is a biobank study, not a treatment trial. It collects samples for future research, so it does not directly test any therapy or provide immediate benefit to participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,000 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
May 2013
- Expected to finish
-
Jun 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals with a confirmed Diagnosis of Primary Hyperoxaluria, Dent Disease, APRT deficiency or Cystinuria. Family members of individuals with these four diseases.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of primary hyperoxaluria (PH) meeting one or more of the following criteria: 1. Liver biopsy documenting alanine-glyoxylate aminotransferase (AGT) activity below the normal reference range confirming PH type 1 OR Liver biopsy documenting glyoxylate reductase/hydroxypyruvate reductase (GR/HPR) activity below the normal reference range confirming PH type 2 2. Molecular genetic analysis (DNA testing) confirming mutations known to cause PH type 1, PH type 2, or PH type 3 3. Urinary oxalate excretion of greater than 0.8 mmol/1.73 m2/day (\>70 mg/1.73 m2/day) in the absence of a identifiable causes of secondary hyperoxaluria, including gastrointestinal disease known to cause enteric hyperoxaluria 4. A patient in end stage kidney failure, in whom neither a liver biopsy nor mutational analysis are available must have: (a) A plasma oxalate concentration of greater than 60 umol/L and a kidney biopsy confirming extensive oxalate deposits OR (b) Evidence of systemic oxalosis 5. Participants in the previous protocol "Tissue Bank of Urine, Blood, and Tissue Samples Collected from the Patients with Primary Hyperoxaluria" 'Mayo IRB #' #80-04. They have already consented to bank their samples and that consent will serve to enroll them in this study. * Diagnosis of Dent disease meeting one or more of the following criteria: 1. Identified mutation of the gene that encodes for chloride exchange transporter 5 (CLCN5) 2. Low molecular weight proteinuria and hypercalciuria 3. Low molecular weight proteinuria and nephrocalcinosis * Diagnosis of APRT disease meeting one or more of the following criteria: 1. Suspected dihydroxyadeninuria and absent APRT enzyme activity measured in red blood cells (RBCs). 2. Homozygosity, or compound heterozygosity, for known disease-causing APRT mutations. 3. Passage of dihydroxyadenine stones (confirmed with stone analysis). * Diagnosis of Cystinuria meeting one or more of the following criteria: 1. Stone analysis demonstrating that the stone contains cystine 2. Increased urinary cystine excretion (\>250 mg/gm creatinine) * Relative of someone with confirmed primary hyperoxaluria, Dent disease, APRT deficiency (also known as dihydroxyadeninuria), or cystinuria Exclusion Criteria: 1. Stone formers who do not meet the inclusion criteria for primary hyperoxaluria, cystinuria, Dent disease, or APRT deficiency. 2. Unwilling or unable to provide consent/assent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aprt deficiency are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can blood and urine markers reveal how rare kidney diseases progress?
- Global registry aims to crack the code of rare kidney stone diseases
- Natural supplement aims to stop painful kidney stones
- Cystinuria drug trial pulled before it even started
- Could a diabetes drug stop painful kidney stones?
- Promising drug may protect kidneys in kids with rare oxalate disorder